Our history

Rooted in high quality science

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities and capital required to manufacture, develop and commercialise its programmed T cell product candidates.

A timeline of our history

2014

Autolus is founded by Dr Martin Pule and is spun-out from UCL

£30 million Series A investment from founding investor Syncona

Publication of RQR8 Safety Switch in Blood

2016

Secures £40 million Series B financing

Doses 1st patients for AUTO1 for pediatric ALL and AUTO6 for Neuroblastoma

Collaboration with CGT Catapult Manufacturing Facility

2017

Doses 1st patients for AUTO2 for Multiple Myeloma, AUTO3 for pALL and DLBCL and AUTO1 for adult ALL

Publication of AUTO4 in Nature Medicine 

2018

Secures $80 million Series C financing

Successful IPO on Nasdaq raising a total of $160.4 million

Publication of Rapacasp9 safety switch in Molecular Therapy 

2019

Opens an office in Maryland, USA

Secures $109 million in public offering

Publication of AUTO1 mechanism of action and pALL Ph1 in Nature Medicine 

2020

Secures $74.2 million in public offering

Starts FELIX trial for AUTO1 in adult ALL

Publication of AUTO6 neuroblastoma Ph1 in Science Translational Medicine 

2021

Publication of AUTO1 mechanism of action in Nature Cancer

Secures $100 million in public offering

Publication of AUTO1 adult ALL Ph1 in Journal of Clinical Oncology

Initiates strategic collaboration with Blackstone, securing up to $250 million to develop obe-cel in adult ALL

1/7
2014
2016
2017
2018
2019
2020
2021